Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Medulloblastoma

Medulloblastoma

31

Pipeline Programs↗

24

Active Trials↗

19

Companies Involved↗

Medulloblastoma is a moderately active landscape with 31 programs across 19 companies. 15 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

32/100

Mech. Concentration

20/100

Completion Rate

63/100

Attrition Rate

19/100

Pipeline

Programs by Phase

Preclinical

No programs

Phase 12

GPC2 CAR T Cells

Stanford University

25 Mci 177lu- DTPA-Omburtamab

Memorial Sloan Kettering Cancer Center

Phase 214

Pemetrexed

Shawn Eagle

Gemcitabine

Johnson & Johnson

Digoxin

Advanz Pharma

Difluoromethylornithine

Cancer Prevention Pharmaceuticals, Inc.

Administration of Drug

Assistance Publique Hopitaux De Marseille

Phase 315

Vincristine

Eli Lilly

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Carboplatin

Avyxa

Cyclophosphamide

Baxter Healthcare Corporation

Vincristine Sulfate

Eli Lilly

Approved

No programs

Analysis

Modality Breakdown

87%

Small molecule

26 of 30 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 30 classified programs, each share of the total. Modality classified for 97% of 31 pipeline programs.

Analysis

Trial Status

58

clinical trials

Completed19 · 33%

Recruiting11 · 19%

Terminated9 · 16%

Active, not recruiting8 · 14%

Not yet recruiting5 · 9%

Unknown status4 · 7%

Other2 · 3%

Clinical Trials

Trial Activity

58 trials

Evaluation of Digoxin for Relapsed Non-WNT, Non-SHH Medulloblastoma

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06701812·23 enrolled

MATCHPOINT - Medulloblastoma Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade

Recruiting·UUniversity of Florida·Phase 1·NCT06514898·12 enrolled

Phase I Clinical Trial of GPC2 Chimeric Antigen Receptor T (GPC2-CAR T) Cells for Relapsed or Refractory Medulloblastoma in Children and Young Adults

Recruiting·SStanford University·Phase 1·NCT07087002·18 enrolled

A Phase I Dose Escalation Trial of Compartmental Radioimmunotherapy (cRIT) Using 177Lu-DTPA-omburtamab in Pediatric and Adolescent Patients With Recurrent or Refractory B7H3 Expressing Primary or Metastatic CNS Tumors

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT07698899·24 enrolled

PNOC044: Liothyronine (L-T3) in Combination With Bevacizumab, Irinotecan and Temozolomide (BIT) for Progressive or Relapsed Medulloblastoma (Cohort 1) or as Monotherapy for Medulloblastoma With Minimal Residual Disease (Cohort 2)

Recruiting·SSabine Mueller, MD, PhD·Preclinical·NCT07346157·69 enrolled

SJiMB21: Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT05535166·130 enrolled

A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children With Average-Risk Medulloblastoma and Reduced Therapy in Children With Medulloblastoma With Low-Risk Features

Recruiting·Children's Oncology Group·Phase 3·NCT05382338·225 enrolled

Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma

Recruiting·—·Phase 2·NCT04696029·118 enrolled

A Pilot Feasibility and Efficacy (Phase 2) Trial of Real Time Drug Screening and Genomic Testing to Determine an Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma

Recruiting·UUniversity of California, San Francisco·Preclinical·NCT05057702·74 enrolled

CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation

Recruiting·SSt. Jude Children's Research Hospital·N/A·NCT07085325·184 enrolled

Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children

Recruiting·—·Phase 2·NCT04501718·44 enrolled

A Phase I/II Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM), and Recurrent/Progressive Medulloblastoma (MB)

Active, not recruiting·UUniversity of Florida·Phase 1·NCT07492316·24 enrolled

Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients With Recurrent Medulloblastoma and Ependymoma

Active, not recruiting·PPediatric Brain Tumor Consortium·Phase 2·NCT04743661·62 enrolled

A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Active, not recruiting·Children's Oncology Group·Phase 2·NCT02724579·45 enrolled

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01878617·660 enrolled

Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)